The effect of argatroban on activated protein C resistance

American Journal of Clinical Pathology

Volumn 131, Issue 6, 2009, Pages 828-833

  Shaikh, Salima ^b   Van Cott, Elizabeth M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

Activated protein C resistance; Anticoagulation; Argatroban; Interference

Indexed keywords

ARGATROBAN; BLOOD CLOTTING FACTOR 5 LEIDEN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; BLOOD CLOTTING TEST; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS;

EID: 67149133284     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPVMUS77ZMBEHJ     Document Type: Article

References (13)

1. Jorquera JI, Montoro JM, Fernandez MA, et al. Modified test for activated protein C resistance [letter]. Lancet. 1994;344:1162-1163. (Pubitemid 24317657)
2. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
3. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508.
4. Staropoli JF, Van Cott EM, Makar RS. Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance [published online ahead of print July 30, 2008]. Transfusion. 2008;48:2435-2441.
5. Saenz A, Van Cott EM. Clinical significance of acquired activated protein C resistance caused by lupus anticoagulants [abstract]. Mod Pathol. 2008;21(suppl):273A. Abstract 1246.
6. Biswas A, Bajaj J, Ranjan R, et al. Factor V Leiden: is it the chief contributor to activated protein C resistance in Asian-Indian patients with deep vein thrombosis? Clin Chim Acta. 2008;392:21-24.
7. Negaard HFS, Iversen PO, Ostenstad B, et al. Increased acquired activated protein C resistance in unselected patients with hematological malignancies. J Thromb Haemost. 2008;6:1482-1487.
8. Marchetti M, Castoldi E, Spronk HMH, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008;112:4061-4068.
9. Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother. 2004;38:25-29. (Pubitemid 38018000)
10. Smogorzewska A, Brandt JT, Chandler WL, et al. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med. 2006;130:1605-1611. (Pubitemid 44683787)
11. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122:782-798. (Pubitemid 28411236)
12. Van Cott EM, Eby C. Antiphospholipid antibodies. In: Kottke-Marchant K, ed. An Algorithmic Approach to Hemostasis Testing. Northfield, IL: College of American Pathologists Press; 2008:295-304.
13. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med. 1997;127:177-185.